About Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals is a company based in St. Louis (United States) founded in 1867 was acquired by Tyco in June 2000.. The company has 2,700 employees as of December 31, 2022. Mallinckrodt Pharmaceuticals has completed 9 acquisitions, including CNS Therapeutics, Ikaria and Ikaria Australia. Mallinckrodt Pharmaceuticals offers products and services including Acthar® Gel and Specialty Generics.
- Headquarter St. Louis, United States
- Employees 2700 as on 31 Dec, 2022
- Stage Public
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mallinckrodt Plc
-
Annual Revenue
$166.2 M19as on Dec 31, 2024
-
Net Profit
$477.9 M1351as on Dec 31, 2024
-
EBITDA
$228.4 M1231as on Dec 31, 2024
-
Latest Funding Round
$26 M (USD), Grant
Oct 15, 2018
-
Investors
Piramal Group
& 2 more
-
Employee Count
2700
as on Dec 31, 2022
-
Investments & Acquisitions
CNS Therapeutics
& 8 more
-
Acquired by
Tyco
(Jun 28, 2000)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals offers a comprehensive portfolio of products and services, including Acthar® Gel and Specialty Generics. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
This product is utilized for treating various medical conditions, with its development focused on improving patient outcomes through established formulation processes.
These are manufactured to provide affordable medical solutions, where distribution is handled to meet healthcare demands in compliance with industry standards.
Unlock access to complete
Unlock access to complete
Leadership Team
31 people
Software Development Team
27 people
Senior Team
15 people
Sales and Marketing
14 people
Finance and Accounting
13 people
Principal Team
9 people
Acute Team
8 people
Legal and Compliance
7 people
Unlock access to complete
Funding Insights of Mallinckrodt Pharmaceuticals
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $26.0M
-
First Round
First Round
(30 Jan 2017)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2018 | Amount | Grant - Mallinckrodt Pharmaceuticals | Valuation |
investors |
|
| Jan, 2017 | Amount | Post-IPO - Mallinckrodt Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Piramal Group, Tyco and Public Health Emergency. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
|
Founded Year | Domain | Location | |
|
Fire, CCTV, and access control security solutions are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mallinckrodt Pharmaceuticals
Mallinckrodt Pharmaceuticals has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include CNS Therapeutics, Ikaria and Ikaria Australia. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of drug delivery system for treating cardiovascular disorders
|
2010 | ||||
|
Biopharmaceuticals for spasticity and chronic pain are developed and supplied.
|
2007 | ||||
|
Therapies for respiratory-related cardiopulmonary disorders are developed.
|
2005 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Mallinckrodt Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mallinckrodt Pharmaceuticals Comparisons
Competitors of Mallinckrodt Pharmaceuticals
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mallinckrodt Pharmaceuticals
Frequently Asked Questions about Mallinckrodt Pharmaceuticals
When was Mallinckrodt Pharmaceuticals founded?
Mallinckrodt Pharmaceuticals was founded in 1867 and raised its 1st funding round 150 years after it was founded.
Where is Mallinckrodt Pharmaceuticals located?
Mallinckrodt Pharmaceuticals is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
How many employees does Mallinckrodt Pharmaceuticals have?
As of Dec 31, 2022, the latest employee count at Mallinckrodt Pharmaceuticals is 2,700.
What is the annual revenue of Mallinckrodt Pharmaceuticals?
Annual revenue of Mallinckrodt Pharmaceuticals is $166.2M as on Dec 31, 2024.
What does Mallinckrodt Pharmaceuticals do?
Manufacturer of specialty pharmaceutical products and diagnostic imaging agents. It develops and markets and specialty pharmaceutical products, biopharmaceutical products, therapies, and nuclear imaging products. Areas of focus include autoimmune diseases and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology, immunotherapy and neonatal respiratory critical care therapies, analgesics, and hemostasis products, and central nervous system drugs. It claims to have received US FDA approvals for 14 products since 2010 and has almost 24 products in the pipeline at various stages of clinical trials for various diseases. An acquired subsidiary of the company Ikaria develops and commercializes critical care therapeutics and interventions designed to address the significant needs of critically ill patients. It offers an FDA-cleared inhaled nitric oxide- a drug to treat hypoxic respiratory failure (HRF) in term and near-term infants, and the INOMAX delivery system (FDA 510(k)- K090958).
What products or services does Mallinckrodt Pharmaceuticals offer?
Mallinckrodt Pharmaceuticals offers Acthar® Gel and Specialty Generics.
How many acquisitions has Mallinckrodt Pharmaceuticals made?
Mallinckrodt Pharmaceuticals has made 9 acquisitions, including CNS Therapeutics, Ikaria, and Ikaria Australia.
Who are Mallinckrodt Pharmaceuticals's investors?
Mallinckrodt Pharmaceuticals has 3 investors. Key investors include Piramal Group, Tyco, and Public Health Emergency.